33rd week of 2012 patent applcation highlights part 46 |
Patent application number | Title | Published |
20120208810 | NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF - The invention relates to the novel materials of formula (I), where: R | 2012-08-16 |
20120208811 | Aminopyrazole Derivative - A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C | 2012-08-16 |
20120208812 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 2012-08-16 |
20120208813 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES - The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): | 2012-08-16 |
20120208814 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors - Tetrahydroquinoline compounds of formula (I) | 2012-08-16 |
20120208815 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE - New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer. | 2012-08-16 |
20120208816 | ORGANIC COMPOUNDS - The present invention provides a compound of formula (I): | 2012-08-16 |
20120208817 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2012-08-16 |
20120208818 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 - The present invention provides compounds of general formula I: | 2012-08-16 |
20120208819 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS - The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases. | 2012-08-16 |
20120208820 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS - Compounds of formula I | 2012-08-16 |
20120208821 | ALPHA ADRENERGIC RECEPTOR MODULATORS - Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described. | 2012-08-16 |
20120208822 | PYRIMIDO-PYRROLO-QUINOXALINEDIONE INHIBITORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND USES THEREFOR - Provided herein are pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity. The compounds, and compositions comprising the compounds, described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, polycystic kidney disease. The compounds may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease. | 2012-08-16 |
20120208823 | New Compounds - Disubstituted tetrahydrofuranyl compounds of general formula I | 2012-08-16 |
20120208824 | ROS Kinase in Lung Cancer - The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of ROS are described, namely proteins encoded by the FIG gene, the SLC34A2 gene, and the CD74 gene. The invention enables new methods for determining the presence of a polypeptide with ROS kinase activity in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer (e.g., an lung cancer). | 2012-08-16 |
20120208825 | CRYSTALLINE AND OTHER FORMS OF 4-AMINO-5-FLUORO-3-[6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL]-1H-Q- UINOLIN-2-ONE LACTIC ACID SALTS - The present invention relates to non-hydrate crystalline forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts, solid pharmaceutical formulations containing the same and methods of use. The present invention also relates to crystalline hydrates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts, pharmaceutical formulations containing the same and methods of use related thereto. The present invention further relates to crystalline solvates of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactic acid salts. | 2012-08-16 |
20120208826 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS - The present invention relates to heterocyclic amide derivatives of Formula (I): Formula (I) wherein the variables are as defined in the specification. The present invention further relates to compositions comprising said heterocyclic amide derivatives of formula (I) and methods for using said heterocyclic amide derivatives of formula (I) for treating or preventing a disease or disorder related to the activity of a protein kinase, in particular, a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal infection. | 2012-08-16 |
20120208827 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS - This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer. | 2012-08-16 |
20120208828 | Azole Derivatives as WTN Pathway Inhibitors - The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas. | 2012-08-16 |
20120208829 | 2-PHENOXY PYRIMIDINONE ANALOGUES - 2-Phenoxy pyrimidinone analogues are provided, of the Formula: | 2012-08-16 |
20120208830 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-am- ino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide - The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I). | 2012-08-16 |
20120208831 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions - The present invention relates to substituted xanthines of general formula | 2012-08-16 |
20120208832 | PROCESS FOR CONVERTING A SOLID (METH)ACRYLATE COPOLYMER INTO A DISPERSED FORM BY MEANS OF A DISPERSING AGENT - The present invention provides a process for converting a solid (meth)acrylate copolymer into a dispersed form by preparing an aqueous dispersion comprising the components (a) a (meth)acrylate copolymer which is composed of free-radical polymerized methyl methacrylate, ethylacrylate and a salt of 2-trimethylammoniumethyl methacrylate, present in solid form as a powder or as a granulate, (b) up to 50% by weight calculated on the (meth)acrylate copolymer (a) of a dispersing agent selected from the groups of (b) i) plasticizers in combination with emulsifiers and/or (b) ii) pharmaceutically acceptable carbohydrates having 6 to 18 carbon atoms with a functional group and (c) water by mixing the components (a), (b) and (c) to give a suspension which becomes an aqueous dispersion during the conversion of the solid (meth)acrylate copolymer into the dispersed form, characterized in that, the (meth)acrylate copolymer is converted into the dispersed form by means of the presence of the dispersing agent at a temperature of less than 50° C. | 2012-08-16 |
20120208833 | 4-(Substituted Anilino)-Quinazoline Derivatives Useful as Tyrosine Kinase Inhibitors - The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors. | 2012-08-16 |
20120208834 | PROCESS FOR PREPARING SPRAY DRIED FORMULATIONS OF 4-[[6-AMINO-5-BROMO-2-[(4-CYANOPHENYL)AMINO]-4-PYRIMIDINYL]OXY]-3,5-DIMET- HYLBENZONITRILE - This invention relates to a process for producing a spray-dried powder comprising microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer. | 2012-08-16 |
20120208835 | Method and dosage regimens for eliminating a chemical substance in blood - A method of reducing the concentration of a chemical or drug substance in the blood plasma comprising titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together is seventy days or more. | 2012-08-16 |
20120208836 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS - Provided herein are compositions and methods for the treatment of obesity and related disorders, including, but not limited to insulin resistance, diabetes, and hepatic steatosis. For example, in some embodiments, pharmaceutically acceptable compositions and methods are provided employing amlexanox, a derivative thereof, or a pharmaceutically acceptable salt thereof, alone or in combination with other agents and/or medical interventions, for the treatment, prevention, and management of such diseases and conditions. | 2012-08-16 |
20120208837 | SUBSTITUTED AZAINDOLES - This invention relates to novel substituted azaindoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing selective inhibitory activity of oncogenic B-Raf | 2012-08-16 |
20120208838 | DIURETICS - A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. | 2012-08-16 |
20120208839 | NEW COMPOUNDS - This invention relates to compounds of formula I | 2012-08-16 |
20120208840 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors - The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R | 2012-08-16 |
20120208841 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator - The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR. | 2012-08-16 |
20120208842 | Novel 1-(1-OXO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)Urea Derivatives As N-FORMYL Peptide Receptor Like-1 (FPRL-1) Receptor Modulators - The present invention relates to novel 1-(1-Oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. | 2012-08-16 |
20120208843 | Method of Using GPR35 to Identify Metabolic-Stabilizing Compounds - The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR35, and b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates to a method for treating or preventing a metabolic-related disorder, comprising administering to an individual in need thereof an effective amount of a GPR35 modulator. | 2012-08-16 |
20120208844 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF - The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. | 2012-08-16 |
20120208845 | Agonists and Antagonists of Human Bitter Taste Receptor TAS2R49 and Uses Thereof - The present invention relates to agonists and antagonists of the human bitter-taste receptor hTAS2R49. The invention also relates to methods for identifying further molecules that suppress or enhance hTAS2R49-mediated bitter taste transduction or bitter taste response and uses thereof. | 2012-08-16 |
20120208846 | Therapeutic Methods For Type I Diabetes - The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds. | 2012-08-16 |
20120208847 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process - Described herein are piperidine and piperazine compounds useful for treating neurodegenerated diseases characterized by a lack of dopamine neuron activity. The compounds are also useful for imaging dopamine neurons. | 2012-08-16 |
20120208848 | GACYCLIDINE FORMULATIONS - Improved formulations of gacyclidine for direct administration to the inner or middle ear. | 2012-08-16 |
20120208849 | METHODS FOR CONTROLLING PAIN IN CANINES USING A TRANSDERMAL SOLUTION OF FENTANYL - This invention provides methods of controlling pain in a canine comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition. | 2012-08-16 |
20120208850 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID - The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions. | 2012-08-16 |
20120208851 | FORMULATIONS - Colloidal suspensions comprising a therapeutic agent and squalene. Squalene binds to certain compounds, such as gacyclidine, much more tightly than other drug carriers, such as polylactic glycolic acid. Including squalene in the particulate phase sequesters the therapeutic agent and provides superior stability at room or body temperature. | 2012-08-16 |
20120208852 | Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof - The present application relates to new, heterocyclyl-substituted 2-acetamido-5-aryl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders. | 2012-08-16 |
20120208853 | PEST CONTROL COMPOSITION - The present invention provides a pest control composition comprising, as active ingredients, an amide compound of the formula (I) [(I) where in R1 and R3 represent, for example, a C1-C6 alkyl group; R2 represent, for example, a Hydrogen atom, a C1-C6 alkyl group; R4 represent, for example, a halogen atom, a C1-C6 alkyl group; R5 represent, for example, a halogen atom, a cyano group; R6 and R7 represent, for example, a halogen atom] and pyriproxyfen; and so on. | 2012-08-16 |
20120208854 | THERAPEUTIC COMBINATION - This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans. | 2012-08-16 |
20120208855 | AMINO-BENZOIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DIHYDROGENASE-RELATED DISORDERS - Provided herein is method of modulating, and in particular decreasing dihydroorotate dehydrogenase (DHODH) activity, as well as a method of treating a DHODH related disease or disorder. | 2012-08-16 |
20120208856 | Heterocyclic Benzoxazole Compositions as Inhibitors of Hepatitis C Virus - This invention relates to benzoxazole compounds, compositions and devices for delivering them, processes for manufacturing them, and methods of using them in the treatment of Hepatitis C Virus. | 2012-08-16 |
20120208857 | Pharmaceutical Compositions - The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections. | 2012-08-16 |
20120208858 | Pharmaceutical Cream Compositions of Oxymetazoline and Methods of Use - The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient. | 2012-08-16 |
20120208859 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES - The invention pertains to compound of Formula (I) wherein X, Y, Z, R | 2012-08-16 |
20120208860 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene. | 2012-08-16 |
20120208861 | IFN TYPE-I PRODUCTION INHIBITOR AND METHOD FOR SCREENING FOR SAME - It has been found that Spi-B, in cooperation with IRF-7, induces type I IFN production. This invention is based on the finding, and provides a type I IFN production inhibitor comprising an antisense nucleic acid or siRNA against Spi-B, or an expression vector capable of expressing the same; a screening method for a substance capable of inhibiting type I IFN production, comprising selecting a substance that suppresses the expression or function of Spi-B as a substance capable of inhibiting type I IFN production; and a type I IFN production inducer comprising an expression vector capable of expressing Spi-B and an expression vector capable of expressing IRF-7 in combination, and the like. | 2012-08-16 |
20120208862 | RIP140 REGULATION OF GLUCOSE TRANSPORT - Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat. | 2012-08-16 |
20120208863 | MODULATION OF GLUT4 GENE PROMOTER ACTIVITY BY AHNAK - Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with obesity, lipotoxicity, hypertension, metabolic syndrome and type 2 diabetes. Preferred agents are double-stranded siRNAs. | 2012-08-16 |
20120208864 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR - The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing. | 2012-08-16 |
20120208865 | EXON SKIPPING THERAPY FOR DYSFERLINOPATHIES - The present invention relates to methods for restoring the function of a mutated dysferlin comprising the step of preventing splicing of one or more exons which encode amino acid sequences that cause said dysferlin dysfunction. Particularly, the splicing of exon 32 is prevented. The present invention also relates to a method for treating a dysferlinopathy in a patient in need thereof, comprising the step of administering to said patient antisense oligonucleotides complementary to nucleic acid sequences that are necessary for correct splicing of one or more exons which encode amino acid sequences that cause said dysfunction. Particularly, the splicing of exon 32 is prevented. | 2012-08-16 |
20120208866 | INTACT MINICELLS AS VECTORS FOR DNA TRANSFER AND GENE THERAPY INVITRO AND INVIVO - A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic acid segment, and (ii) bringing the minicells into contact with mammalian cells that are engulfing-competent, such that the minicells are engulfed by the mammalian cells, which thereafter produce an expression product of the first nucleic acid segment. | 2012-08-16 |
20120208867 | HMGB1 BINDING NUCLEIC ACID MOLECULE AND APPLICATIONS THEREOF - A nucleic acid molecule that can bind to HMGB1 protein and applications thereof are provided. A nucleic acid molecule having a dissociation constant for HMGB1 protein of 5×10 | 2012-08-16 |
20120208868 | PURIFICATION PROCESS OF NASCENT DNA - The present invention relates to the use of purified nascent DNA for the implementation of a process allowing the mapping and the numbering of the active DNA replication origins of multi cellular eukaryotic cells, and the characterisation of the sequence of the replication origins. | 2012-08-16 |
20120208869 | Endometriosis-Related Markers and Uses Thereof - The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy. | 2012-08-16 |
20120208870 | HEPATITIS C VIRUS CODON OPTIMIZED NON-STRUCTURAL NS3/4A FUSION GENE - Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection. | 2012-08-16 |
20120208871 | USE OF TOLL-LIKE RECEPTOR AND AGONIST FOR TREATING CANCER - The present invention is directed to methods and agents used for treating cancer or infectious diseases by providing toll-like receptors such as toll-like receptor 5 (TLR-5) in combination with providing a toll-like receptor agonists such as flagellin resulting in a cis and intrans effect that recruits cells involved in both the innate (cis effect) and adaptive (trans effect) immune response to specifically kill cancer cells and cells infected with a pathogen via the NF-κB apoptosis pathway. | 2012-08-16 |
20120208872 | USE OF TEA POLYPHENOLS FOR TREATING AND/OR PREVENTING NICOTINE OR NICOTINE-DERIVED COMPOUNDS OR ESTROGEN INDUCED BREAST CANCER - This invention relates to methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer. | 2012-08-16 |
20120208873 | TEA POLYPHENOLS PRODUCTS FOR CEASING SMOKING AND TREATING AND/OR PREVENTING NICOTINE OR NICOTINE-DERIVED COMPOUNDS OR ESTROGEN INDUCED BREAST CANCER - This invention relates to methods of aiding smoking cessation and/or treating and/or preventing smoking addition or methods of treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer, which comprises administering to a subject an effective amount of a tea polyphenol. The invention uses catechins (such as epigallocatechin gallate (“EGCG”), epigallocatechin (“EGC”), epicatechin gallate (“ECG”), epicatechin (“EC”), gallocatechin gallate (“GCG”), gallocatechin (“GC”), catechin gallate (“CG”) and catechin (“C”)) in aiding smoking cessation and/or treating and/or preventing smoking addition or treating and/or preventing nicotine or nicotine-derived compounds or estrogen induced breast cancer. | 2012-08-16 |
20120208874 | SUBSTITUTED ALKYNYL PHENOXY COMPOUNDS AS NEW SYNERGISTS IN PESTICIDAL COMPOSITIONS - A composition comprising an alkynyl phenoxy compound of Formula (I) as a synergist and a pesticidal active ingredient is described, wherein R | 2012-08-16 |
20120208875 | METHOD FOR INHIBITING BLOOD VESSEL STENOSIS - Provided is a method for inhibiting blood vessel stenosis in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from a group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound, and combinations thereof. Also provided is a method for inhibiting blood vessel stenosis in a subject, comprising administration to the subject an effective amount of an | 2012-08-16 |
20120208876 | AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN - The invention relates to compounds, to compositions comprising the same and uses thereof for the prevention or treatment of pain, e.g neuropathic pain while having neutral or beneficial effect on metabolic parameters. | 2012-08-16 |
20120208877 | Skin treatment in antiseptic thin film form with silver - A skin treating and antibacterial composition, consisting essentially water, emollient, emulsifier, humectant, thickener, silver or silver citrate, and additional ingredients, and providing a superior hand lotion. | 2012-08-16 |
20120208878 | MEDICAL COMPOSITION - The object of the invention is to find the actions of the crude drugs contained in Daikenchuto or their components and the synergistic effect of the components with one another or with other pharmacologically active substances, and to provide new drugs or pharmaceutical compositions based on the findings. The invention is directed to intestinal peristaltic motility-enhancers comprising an effective amount of hydroxy-α-sanshool or a plant containing the same or an extract thereof; compositions comprising a combination of hydroxy-α-sanshool or a plant containing the same or an extract thereof and capsaicin or a plant containing the same or an extract thereof or bethanechol or a salt thereof; as well as a method for improving intestinal motility which comprises administering the composition to a patient. | 2012-08-16 |
20120208879 | METHODS AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING PSORIASIS - Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided. | 2012-08-16 |
20120208880 | (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUORMETHYLPHENYL)-AMIDE TABLET FORMULATIONS WITH IMPROVED STABILITY - The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis. | 2012-08-16 |
20120208881 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 2012-08-16 |
20120208882 | Organic Compounds - The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD). | 2012-08-16 |
20120208883 | TREATMENT OF ONCOLOGICAL DISEASES - The present invention relates to the use of acetyl L-carnitine for the preparation of a medicament for the prevention and/or treatment of cancer. Methods of preventing and/or treatment of cancer by administering an effective amount of acetyl L-carnitine to subject in need thereof are also disclosed. | 2012-08-16 |
20120208884 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 2012-08-16 |
20120208885 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 2012-08-16 |
20120208886 | Moisture Resistant Container Systems for Rapidly Bioavailable Dosage Forms - Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms. | 2012-08-16 |
20120208887 | STABLE, LIQUID, READY-TO-USE KETOPROFEN FORMULATIONS - Stable, liquid, ready-to-use ketoprofen formulation for parenteral administration are provided. In some embodiments, the formulation comprises ketoprofen solubilized in a solely aqueous solvent comprising a buffering agent, wherein the composition has a pH of about 5.5 to about 6.5. | 2012-08-16 |
20120208888 | Biocide compositions and related methods - The invention relates to biocide compositions comprising organic acyl polyoxychlorine and methods for producing said biocide compositions. The biocide compositions form reactive oxygen species when contacted by microorganisms, proteinaceous substances, and oxidizable organic based contaminants. | 2012-08-16 |
20120208889 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF - HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein. | 2012-08-16 |
20120208890 | STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 2012-08-16 |
20120208891 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 2012-08-16 |
20120208892 | EMESIS TREATMENT - A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino) tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino) tetralin compound in which the ratio of the S and R enantiomers is at least 2:1. | 2012-08-16 |
20120208893 | NUTRITIONAL COMPOSITIONS FOR MODULATING INFLAMMATION INCLUDING EXOGENOUS VITAMIN K2 - Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof. | 2012-08-16 |
20120208894 | MULTI-PURPOSE HAND DISINFECTANT - A multi-purpose hand disinfectant and in particular, a hand disinfectant which meets the FDA (Food and Drug Administration) requirements for use both as an antiseptic handwash or health-care personnel handwash drug product and as a surgical hand scrub drug product is described herein. | 2012-08-16 |
20120208895 | COMPOSITE MATERIAL WITH PROPERTIES OF SELF-HEALING AND RELEASE OF ACTIVE INGREDIENTS, FOR BIOMEDICAL APPLICATIONS - This invention relates to a composite material for biomedical applications, in particular dental applications, which possesses self-healing capacity and is able to incorporate a system for the release of active ingredients at the stage of application and use. | 2012-08-16 |
20120208896 | AMINO ACID DERIVATIVES AND ABSORABLE POLYMERS THEREFROM - The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile. | 2012-08-16 |
20120208897 | METHOD FOR PREPARING ACETYLATED DERIVATIVES OF AN AMYLACEOUS MATERIAL - The present invention relates to a continuous method for preparing acetylated derivatives of an amylaceous material. The invention also relates to a solid composition of at least one acetylated derivative of an amylaceous material obtained by means of said method. The invention finally relates to the use of such a composition to prepare thermoplastic, elastomeric, adhesive, pharmaceutical and/or ink compositions. | 2012-08-16 |
20120208898 | Viscous Liquid Cleansing Compositions Comprising Sulfonated Fatty Acids, Esters, or Salts Thereof and Betaines or Sultaines - Formulations of personal care compositions and personal care concentrate compositions containing salts of sulfonated fatty acid esters and/or salts of sulfonated fatty acids, and an alkyl betaine or sultaine are described. Personal care compositions of the present technology include liquid hand soaps, bath and shower washes, shampoos, 2-in-1 or 3-in-1 shampoos, antidandruff shampoo, facial cleaners, among others. | 2012-08-16 |
20120208899 | Tool for Assessment of Symptoms of Irritable Bowel Syndrome - Methods of treating and/or diagnosing irritable bowel syndrome (IBS) are provided, wherein treatment or diagnosis is undertaken on the basis of the patient's recordation of events associated with IBS in an event log and/or symptom diary. | 2012-08-16 |
20120208900 | METHODS OF PREDICTING THE NEED FOR SURGERY IN CROHN'S DISEASE - The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment. | 2012-08-16 |
20120208901 | DEFOAMING METHOD AND DEVICE - Provided are a deforming method and device that use laser-induced breakdown. The provided method and device make it possible to shorten the focal distance, thereby improving laser beam convergence, and increase the utilization efficiency of sound waves that contribute to defoaming. Pulsed laser light is focused and irradiated into a space inside an acoustic waveguide ( | 2012-08-16 |
20120208902 | ENHANCEMENT OF FISCHER-TROPSCH PROCESS FOR HYDROCARBON FUEL FORMULATION - An enhanced Fischer-Tropsch process for the synthesis of sulfur free, clean burning, green hydrocarbon fuels, examples of which include syndiesel and aviation fuel. Naphtha is destroyed in a hydrogen generator and recycled as feedstock to a syngas (FT) reactor in order to enhance the production of syndiesel from the reactor. A further variation integrates a second hydrogen generator capturing light hydrocarbon gas for conversion to hydrogen and carbon monoxide which supplements the Fischer-Tropsch reactor. The result is a considerable increase in the volume of syndiesel formulated. A system for effecting the process is also characterized in the specification. | 2012-08-16 |
20120208903 | METHOD FOR CONVERSION OF CARBON DIOXIDE TO METHANE USING VISIBLE AND NEAR INFRA-RED LIGHT - The invention relates to a method for converting carbon dioxide to methane. The method comprises exposing carbon dioxide adsorbed on a nanoporous silicate matrix to light in the presence of a source of carbon dioxide and a source of hydrogen for a time and under conditions sufficient to convert carbon dioxide to methane. The matrix contains at least one photochromic metal oxide entity, and contains a C | 2012-08-16 |
20120208904 | METHOD FOR PRODUCING A MULTIMETALLIC SULFUREOUS SOLID AND USE THEREOF AS A CATALYST IN A METHOD FOR PRODUCING HIGHER ALCOHOLS FROM SYNTHESIS GAS - The present invention relates to a sulphided multi-metallic catalyst, a process for obtaining it by preparing a metal mixture and subsequent sulphidation thereof and its use in a process for producing higher alcohols (C | 2012-08-16 |
20120208905 | CATALYST COMPOSITION FOR PRODUCING HYDROCARBONS AND METHOD FOR PRODUCING HYDROCARBONS - There are provided a catalyst composition for producing hydrocarbons and a method for producing hydrocarbons which exhibit a high CO conversion rate, generates minimal amount of gaseous components, and is also capable of efficiently obtaining, from a syngas, a gasoline fraction which is selective for and rich in the components having a high octane number, such as aromatic, naphthenic, olefinic and branched paraffinic hydrocarbons, by using a Fischer-Tropsch synthesis catalyst that contains at least one type of metal exhibiting activity in Fischer-Tropsch reaction and manganese carbonate and a zeolite serving as a solid acid. | 2012-08-16 |
20120208906 | Endless flexible members for imaging devices - Flexible members for use in imaging devices comprise a polyphenylsulfone and a polyetherimide; and optionally, a polysiloxane surfactant. | 2012-08-16 |
20120208907 | Endless flexible members for imaging devices - Flexible members for use in imaging devices comprise a polyamic acid and an internal release agent; and optionally, a polysiloxane surfactant. | 2012-08-16 |
20120208908 | METHOD AND DEVICE FOR PROVIDING A RAW MATERIAL FOR THE PRODUCTION OF PET CONTAINERS - A method and a device for providing a raw material for the production of PET containers, the raw material being mixed from recycled PET (r-PET) and virgin PET (v-PET), where in order to optimize both the plant and the method, v-PET is added in a quantitatively controlled manner to the r-PET prior to the last heating of the r-PET or to the heated r-PET. | 2012-08-16 |
20120208909 | POLYMER MIXTURES OF POLYSTYRENE HAVING STYRENE BUTADIENE BLOCK COPOLYMERS - The invention relates to a mixture comprising: a) 1 to 40% by weight of a styrene-butadiene-styrene block copolymer having 1.) 60 to 95% by weight of styrene monomer and 2.) 5 to 50% by weight of diene monomer; b) 60 to 99% by weight of styrene polymer; c) 0 to 50% by weight of a filler; and d) 0.1 to 20% by weight of a foaming additive, the sum of the components a) to d) being 100% by weight. | 2012-08-16 |